Literature DB >> 10198798

New vaccines against tuberculosis. The status of current research.

I M Orme1.   

Abstract

The increasing realization that the current vaccine for tuberculosis, bacille Calmette-Guérin (BCG), is of varying effectiveness, and is less protective in adults than in children, has prompted new research for a replacement. New research has resulted in innovative approaches, including the use of sub-unit vaccines, auxotropic vaccines, DNA vaccines, and recombinant vaccines, among others. This article reviews these approaches and test results in animal models, and discusses their potential for use in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198798     DOI: 10.1016/s0891-5520(05)70049-0

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  13 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Effective vaccination against tuberculosis-a new ray of hope.

Authors:  J M Grange
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

3.  Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode.

Authors:  J Turner; E R Rhoades; M Keen; J T Belisle; A A Frank; I M Orme
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Current and Future Use of Vaccines for Viral and Bacterial Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

Review 5.  [Immunization: leaps into the future. Tuberculosis vaccines].

Authors:  N Martínez Alsina; R Sastre de la Fuente
Journal:  Aten Primaria       Date:  2002-10-15       Impact factor: 1.137

6.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 7.  Vaccine development for tuberculosis: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

8.  The ΔfbpA attenuated candidate vaccine from Mycobacterium tuberculosis, H37Rv primes for a stronger T-bet dependent Th1 immunity in mice.

Authors:  Cherie M Roche; Amanda Smith; Devin R Lindsey; Akshay Meher; Kimberly Schluns; Ashish Arora; Lisa Y Armitige; Chinnaswamy Jagannath
Journal:  Tuberculosis (Edinb)       Date:  2011-11-13       Impact factor: 3.131

9.  The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Authors:  Lise Brandt; Yasir A W Skeiky; Mark R Alderson; Yves Lobet; Wilfried Dalemans; Oliver C Turner; Randall J Basaraba; Angelo A Izzo; Todd M Lasco; Philip L Chapman; Steven G Reed; Ian M Orme
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

10.  Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis.

Authors:  M Gonzalez-Juarrero; I M Orme
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.